June 9, 2020 11:29 AM EDTUpdated 11:41 AM
Financing
Startups

Go­ing where PRO­TACs can't, Ver­sant un­veils $50M bet on Car­olyn Bertozzi's LY­TAC tech — with a ris­ing star at the helm

Amber Tong

When the first pro­tein degra­da­tion com­pa­nies an­nounced them­selves to the biotech world around 2013, wield­ing PRO­TACs — pro­te­ol­y­sis tar­get­ing chimeras — they promised to break the rules …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times